UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Clinical and Applied Thrombosis/Hemostasis, 2021, Vol.27, p.10760296211021498

2021

Volltextzugriff (PDF)

Risk Minimization of Antibody–Drug Conjugates in Oncology: A Review

Drug safety, 2021-07, Vol.44 (7), p.733-742

2021

Volltextzugriff (PDF)

An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations

Clinical and applied thrombosis/hemostasis, 2022-01, Vol.28, p.10760296211056648

2022

Volltextzugriff (PDF)

Development and Implementation of an Online Global Pharmacovigilance Certificate Program During the COVID-19 Pandemic

Clinical and applied thrombosis/hemostasis, 2022, Vol.28, p.107602962211151-10760296221115112

2022

Volltextzugriff (PDF)

The importance of cross‐disciplinary scientific engagement in the development of quantitative procedures for aggregate safety assessments

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2019-10, Vol.18 (5), p.510-512

2019

Volltextzugriff (PDF)

Issues Associated with and Recommendations for Using PCR To Detect Outbreaks of Pertussis

Journal of Clinical Microbiology, 2002-08, Vol.40 (8), p.2801-2805

2002

Volltextzugriff (PDF)

Long-term safety from the raltegravir clinical development program

Current HIV research, 2011-01, Vol.9 (1), p.40

2011

Volltextzugriff (PDF)

Best-practices for the design and development of prescription medication information: A systematic review

Patient education and counseling, 2018-08, Vol.101 (8), p.1351-1367

2018

Volltextzugriff (PDF)

Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine

Vaccine, 2015-06, Vol.33 (29), p.3422-3428

2015

Volltextzugriff (PDF)

The future of safety science is happening now: The modernization of the benefit‐risk paradigm

Pharmacoepidemiology and drug safety, 2017-08, Vol.26 (8), p.869-874

2017

Volltextzugriff (PDF)

Lack of Evidence of Measles Virus Shedding in People with Inapparent Measles Virus Infections

The Journal of infectious diseases, 2004-05, Vol.189 (Supplement-1), p.S165-S170

2004

Volltextzugriff (PDF)

Digital Additional Risk Minimization Measures: An Exploratory Study Using Qualitative Feedback from Healthcare Professionals and Patients Across Six Countries

Pharmaceutical medicine, 2022-02, Vol.36 (1), p.21-32

2022

Volltextzugriff (PDF)

Abstract 4227: Treatment regimens, treatment duration, and between-treatment duration in patients with small cell lung cancer across lines of therapy: An analysis of electronic health records data

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4227-4227

2018

Volltextzugriff (PDF)

Abstract 4228: Incidence of pericardial and pleural effusions in patients with small cell lung cancer treated with third-line or later-line therapy: An analysis of electronic health records data

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4228-4228

2018

Volltextzugriff (PDF)

Abstract 1213: Comorbidities and concomitant medication use in small cell lung cancer patients treated with third and later-lines of therapy: An analysis of electronic health records data

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1213-1213

2018

Volltextzugriff (PDF)

Incidence of pre-treatment and off-treatment pericardial and pleural effusions by line of therapy in patients with small cell lung cancer: An analysis of electronic health records data

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e20569-e20569

2018

Volltextzugriff (PDF)

Measles, mumps, and rubella virus vaccine (M-M-R(TM)II): A review of 32 years of clinical and postmarketing experience

Vaccine, 2012-11, Vol.30 (48), p.6918

2012

Volltextzugriff (PDF)

Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience

Vaccine, 2012-11, Vol.30 (48), p.6918-6926

2012

Volltextzugriff (PDF)

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Clinical and applied thrombosis/hemostasis, 2021-01, Vol.27

2021

Volltextzugriff (PDF)

Pharmacovigilance

1, 2018

Volltextzugriff (PDF)

No Adverse Signals Observed After Exposure to Human Papillomavirus Type 6/11/16/18 Vaccine During Pregnancy: 6-Year Pregnancy Registry Data

Obstetrics and gynecology (New York. 1953), 2014-05, Vol.123 Suppl 1 (Supplement 1), p.93S-93S

2014

Volltextzugriff (PDF)

1050Evaluation of syncope and related events following vaccination with quadrivalent human papillomavirus vaccine (2006-2013)

Open forum infectious diseases, 2014-12, Vol.1 (suppl_1), p.S307-S308

2014

Volltextzugriff (PDF)

An Alternative to Disproportionality: A Frequency-Based Method for Pharmacovigilance Data Mining

Therapeutic innovation & regulatory science, 2018-05, Vol.52 (3), p.294-299

2018

Volltextzugriff (PDF)

Etiologies of Rash and Fever Illnesses in Campinas, Brazil

The Journal of infectious diseases, 2011-09, Vol.204 (suppl_2), p.S627-S636

2011

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(20)
Infectious Diseases
(11)
Microbiology
(11)
Immunology
(10)
Adolescent
(8)
Measles
(8)
Child
(7)
Child, Preschool
(7)
Adult
(6)
Biological And Medical Sciences
(6)
Epidemiology
(6)
Female
(6)
Vaccination
(6)
Fundamental And Applied Biological Sciences. Psychology
(5)
Immunization
(5)
Incidence
(5)
Infant
(5)
Measles - Epidemiology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Risk Minimization of Antibody–Drug Conjugates in Oncology: A Review

An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations

Development and Implementation of an Online Global Pharmacovigilance Certificate Program During the COVID-19 Pandemic

The importance of cross‐disciplinary scientific engagement in the development of quantitative procedures for aggregate safety assessments

Issues Associated with and Recommendations for Using PCR To Detect Outbreaks of Pertussis

Long-term safety from the raltegravir clinical development program

Best-practices for the design and development of prescription medication information: A systematic review

Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine

The future of safety science is happening now: The modernization of the benefit‐risk paradigm

Lack of Evidence of Measles Virus Shedding in People with Inapparent Measles Virus Infections

Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data

Digital Additional Risk Minimization Measures: An Exploratory Study Using Qualitative Feedback from Healthcare Professionals and Patients Across Six Countries

Abstract 4227: Treatment regimens, treatment duration, and between-treatment duration in patients with small cell lung cancer across lines of therapy: An analysis of electronic health records data

Abstract 4228: Incidence of pericardial and pleural effusions in patients with small cell lung cancer treated with third-line or later-line therapy: An analysis of electronic health records data

Abstract 1213: Comorbidities and concomitant medication use in small cell lung cancer patients treated with third and later-lines of therapy: An analysis of electronic health records data

Incidence of pre-treatment and off-treatment pericardial and pleural effusions by line of therapy in patients with small cell lung cancer: An analysis of electronic health records data

Measles, mumps, and rubella virus vaccine (M-M-R(TM)II): A review of 32 years of clinical and postmarketing experience

Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Pharmacovigilance

No Adverse Signals Observed After Exposure to Human Papillomavirus Type 6/11/16/18 Vaccine During Pregnancy: 6-Year Pregnancy Registry Data

1050Evaluation of syncope and related events following vaccination with quadrivalent human papillomavirus vaccine (2006-2013)

An Alternative to Disproportionality: A Frequency-Based Method for Pharmacovigilance Data Mining

Etiologies of Rash and Fever Illnesses in Campinas, Brazil

Suchergebnisse filtern